http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Lakshmi Dutta (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Lakshmi Dutta,Dushmanta Kumar Das 제어·로봇·시스템학회 2021 International Journal of Control, Automation, and Vol.19 No.7
This paper proposed an adaptive explicit nonlinear model predictive control (AENMPC) technique using multiple estimation models with a convex combination framework [18] for a class of nonlinear MIMO systems. Here, the explicit solution for the control signal is obtained from an optimal performance index which can be formulated without online optimization. In this work, a closed-form control law is developed by approximating the tracking error in the receding horizon by its Taylor series expansion. The control performance of any modelbased control technologies explicitly depends on the quality of the unknown system parameters, hence an adaptive parameter estimator is used to estimate the system parameter online [16,17]. To ensure the boundedness of the estimated parameter within a predefined compact region, a projection based adaptive law is used [43]. Using an aerodynamic laboratory set-up, known as the twin-rotor multi-input multi-output system (TRMS), the effectiveness of the proposed control algorithm has been verified. The complete state information of the system to the proposed adaptive controller is given from an extended Kalman filter based state observer. The performance of the proposed adaptive control algorithm has been verified successfully in simulations as well as real-time experimental setup of the TRMS model and compared with an existing control approach.
-
Nagendra Lakshmi,Dutta Deep,Girijashankar Harish Bukkasagar,Khandelwal Deepak,Lathia Tejal,Sharma Meha 대한소아내분비학회 2024 Annals of Pediatirc Endocrinology & Metabolism Vol.29 No.2
Purpose: Sodium glucose cotransporter-2 inhibitors (SGLT2i) have been evaluated in children with type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM), and several other nondiabetic conditions. Potential tolerability issues have prevented the routine use of SGLT2i in children with diabetes. However, no meta-analysis to date has evaluated the safety and tolerability of SGLT2i in children. This systematic review and meta-analysis aimed to address this knowledge gap.Methods: Databases were searched for randomized controlled trials (RCTs), case control, and cohort studies involving children receiving SGLT2i in the intervention-arm. Primary outcome was occurrence of treatment emergent adverse events (TAEs). Secondary outcomes were evaluation of glycemic efficacy and occurrence of severe adverse events (SAEs), hypoglycemia, ketosis, genital or urinary infections, and any other adverse events.Results: From the 27 articles initially screened, data from 4 RCTs (258 children) were analyzed. In children with T2DM, occurrence of TAEs (odds ratio [OR], 1.77; 95% confidence interval [CI], 0.93–3.36; <i>P</i>=0.08; <i>I</i><sup>2</sup>=0%), SAEs (OR, 0.45; 95% CI, 0.08–2.54; <i>P</i>=0.37; <i>I</i><sup>2</sup>=0%), ketoacidosis (OR, 0.33; 95% CI, 0.01–8.37; <i>P</i>=0.50), urinary tract infections (OR, 2.34; 95% CI, 0.44–12.50; <i>P</i>=0.32; <i>I</i><sup>2</sup>=0%), and severe hypoglycemia (OR, 4.47; 95% CI, 0.21–96.40; <i>P</i>=0.34) were comparable among the SGLTi group and placebo. Compared to placebo, T2DM children receiving SGLTi had significantly lower glycosylated hemoglobin at 24–26 weeks (mean difference [MD], -0.79%; 95% CI, -1.33 to -0.26; <i>P</i>=0.004; <i>I</i><sup>2</sup>=0%). In T1DM children, β-hydroxybutyrate levels were significantly higher in the SGLTi group than the placebo group (MD, 0.11 mmol/L; 95% CI, 0.05–0.17; <i>P</i>=0.0005; <i>I</i><sup>2</sup>=53%). In T1DM, there was not a single report of an SAE, ketoacidosis, or severe hypoglycemia in either the placebo or treatment groups, but time-in-range was considerably greater in the SGLT2i group than the placebo group (68%±6% vs. 50%±13%, <i>P</i><0.001).Conclusion: SGLT2i use in children and young adults appears to be both safe and tolerable based on our meta-analyses and review of the literature.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
